Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.86 USD
Change Today -0.0178 / -2.04%
Volume 84.7K
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

dara biosciences inc (DARA) Key Developments

DARA BioSciences, Inc Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reaffirms Revenue Guidance for the Full Year of 2015

DARA BioSciences Inc. announced earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net product revenues of $990,800 compared to $409,400 a year ago. Net loss attributable to controlling interest was $2,684,100 or $0.14 per share compared to $2,583,100 or $0.24 per share a year ago. The increase in Revenue was primarily attributable to the expanded commercial sales organization and ongoing success in generating interest and prescriptions across DARA's oncology supportive care product portfolio. The loss attributable to controlling interest for the current quarter was $101,000 more than the same period last year. For the six months, the company reported net product revenues of $1,643,000 compared to $570,900 a year ago. Net loss attributable to controlling interest was $5,835,200 compared to $5,241,100 a year ago. Based on current trends and continued growth DARA continues to support previous guidance of $3.7 million for Gelclair and Soltamox net sales for the full year 2015, excluding any net revenue contribution from the launch of Oravig later in the year.

DARA BioSciences, Inc to Report Q2, 2015 Results on Aug 12, 2015

DARA BioSciences, Inc announced that they will report Q2, 2015 results After-Market on Aug 12, 2015

DARA BioSciences, Inc, Q2 2015 Earnings Call, Aug 13, 2015

DARA BioSciences, Inc, Q2 2015 Earnings Call, Aug 13, 2015

Midatech Pharma Plc, DARA BioSciences, Inc - M&A Call

To discuss the Midatech Pharma Plc's proposed acquisition of DARA BioSciences, Inc.

NASDAQ Grants Additional 180-Day Period To DARA BioSciences To Regain Compliance

On May 19, 2015, DARA BioSciences, Inc, received a notification letter from the Listing Qualifications Department of The NASDAQ Stock Market (NASDAQ) indicating that the NASDAQ Listing Qualifications Staff has granted the company's request for an additional 180-day period in which to regain compliance with the minimum $1.00 bid price per share requirement. The NASDAQ Listing Qualifications Staff's determination to grant the additional 180 day compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the NASDAQ Capital Market, with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the additional 180-day compliance period by effecting a reverse stock split, if necessary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DARA:US $0.86 USD -0.0178

DARA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abeona Therapeutics Inc $4.64 USD -0.03
View Industry Companies
 

Industry Analysis

DARA

Industry Average

Valuation DARA Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DARA BIOSCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.